CN1558916A - 产生嵌合异源多聚体的组合物和方法 - Google Patents

产生嵌合异源多聚体的组合物和方法 Download PDF

Info

Publication number
CN1558916A
CN1558916A CNA02818596XA CN02818596A CN1558916A CN 1558916 A CN1558916 A CN 1558916A CN A02818596X A CNA02818596X A CN A02818596XA CN 02818596 A CN02818596 A CN 02818596A CN 1558916 A CN1558916 A CN 1558916A
Authority
CN
China
Prior art keywords
chain
binding unit
antigen binding
sequence
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA02818596XA
Other languages
English (en)
Chinese (zh)
Inventor
王材力
钟平宇
刘胜江
罗培志
李胜峰
王欣慰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abmaxis Inc
Original Assignee
Abmaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abmaxis Inc filed Critical Abmaxis Inc
Publication of CN1558916A publication Critical patent/CN1558916A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CNA02818596XA 2001-08-01 2002-07-31 产生嵌合异源多聚体的组合物和方法 Pending CN1558916A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/921,144 US6833441B2 (en) 2001-08-01 2001-08-01 Compositions and methods for generating chimeric heteromultimers
US09/921,144 2001-08-01

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910149285A Division CN101654483A (zh) 2001-08-01 2002-07-31 产生嵌合异源多聚体的组合物和方法

Publications (1)

Publication Number Publication Date
CN1558916A true CN1558916A (zh) 2004-12-29

Family

ID=25444981

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA02818596XA Pending CN1558916A (zh) 2001-08-01 2002-07-31 产生嵌合异源多聚体的组合物和方法
CN200910149285A Pending CN101654483A (zh) 2001-08-01 2002-07-31 产生嵌合异源多聚体的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910149285A Pending CN101654483A (zh) 2001-08-01 2002-07-31 产生嵌合异源多聚体的组合物和方法

Country Status (7)

Country Link
US (2) US6833441B2 (https=)
EP (1) EP1421117B1 (https=)
JP (2) JP2005506064A (https=)
CN (2) CN1558916A (https=)
CA (1) CA2455237C (https=)
MX (1) MXPA04001053A (https=)
WO (1) WO2003012069A2 (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459346A (zh) * 2009-04-27 2012-05-16 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN106905435A (zh) * 2017-03-13 2017-06-30 武汉海沙百得生物技术有限公司 一种制备基于蛋白a突变体的结合蛋白的方法
US9879084B2 (en) 2011-09-23 2018-01-30 Oncomed Pharmaceuticals, Inc. Modified immunoglobulin molecules that specifically bind human VEGF and DLL4
CN108473556A (zh) * 2015-12-03 2018-08-31 Ucb生物制药私人有限公司 多特异性抗体
WO2018205755A1 (zh) * 2017-05-09 2018-11-15 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002332598A1 (en) * 2001-08-22 2003-03-10 Shengfeng Li Compositions and methods for generating antigen-binding units
WO2003066660A2 (en) * 2002-02-05 2003-08-14 Immunolex Therapeutics Aps A PAIR OF ANTIBODY Fv FRAGMENTS STABILIZED BY COILED­COIL PEPTIDES
US20030157091A1 (en) * 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20050147962A1 (en) * 2002-11-19 2005-07-07 Wagstrom Christopher R. Display of dimeric proteins on phage
JP2007502837A (ja) * 2003-08-18 2007-02-15 テシス バイオサイエンス， インコーポレイテッド 小型エピトープ抗体を使用するサンプルの複雑さを低減するための方法
EP3050963B1 (en) 2005-03-31 2019-09-18 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
JP2007008925A (ja) * 2005-05-31 2007-01-18 Canon Inc 標的物質捕捉分子
JP4766528B2 (ja) * 2005-06-27 2011-09-07 株式会社メニコン 自己組織化ペプチドおよびそれより得られるゲル
AR056142A1 (es) * 2005-10-21 2007-09-19 Amgen Inc Metodos para generar el anticuerpo igg monovalente
GB2433591A (en) * 2005-12-20 2007-06-27 Sharp Kk Method for functionalising a hydrophobic substrate
GB2433506A (en) * 2005-12-20 2007-06-27 Sharp Kk A method of producing a multimeric capture agent
GB2433505A (en) * 2005-12-20 2007-06-27 Sharp Kk Capture agents for binding a ligand
CA2645159A1 (en) * 2006-03-10 2008-06-26 Michael S. Urdea Multiplex protein fractionation
US8871912B2 (en) 2006-03-24 2014-10-28 Merck Patent Gmbh Engineered heterodimeric protein domains
ES2892925T3 (es) 2006-03-31 2022-02-07 Chugai Pharmaceutical Co Ltd Métodos para controlar la farmacocinética en sangre de anticuerpos
JP5368301B2 (ja) 2006-06-22 2013-12-18 ノボ・ノルデイスク・エー／エス 可溶性ヘテロ二量体レセプター及びその使用
WO2007147901A1 (en) * 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
WO2008027236A2 (en) * 2006-08-30 2008-03-06 Genentech, Inc. Multispecific antibodies
FI120376B (fi) * 2007-01-17 2009-09-30 Next Biomed Technologies Nbt O Menetelmä biomuokatun, korkean affiniteetin polypeptidin valmistamiseksi
FI120349B (fi) 2007-03-07 2009-09-30 Next Biomed Technologies Nbt O Menetelmä fuusiopolypeptidin valmistamiseksi
CN101772574B (zh) 2007-08-21 2016-01-06 莫佛塞斯公司 改良的用于二硫键形成的方法
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8691730B2 (en) 2007-09-14 2014-04-08 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
AU2008304748C1 (en) 2007-09-26 2014-06-12 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
ES2447875T3 (es) 2007-10-02 2014-03-13 Theranos, Inc. Dispositivos modulares para punto de cuidados y usos de los mismos
US8637435B2 (en) * 2007-11-16 2014-01-28 Merck Sharp & Dohme Corp. Eukaryotic cell display systems
CA2715212A1 (en) 2008-03-03 2009-09-11 Glycofi, Inc. Surface display of recombinant proteins in lower eukaryotes
CN102143977B (zh) * 2008-09-03 2014-08-06 霍夫曼-拉罗奇有限公司 多特异性抗体
PE20120591A1 (es) 2009-04-02 2012-05-23 Roche Glycart Ag Anticuerpos multiespecificos que comprenden anticuerpos de longitud completa y fragmentos fab de cadena sencilla
KR20120108967A (ko) 2009-09-16 2012-10-05 제넨테크, 인크. 코일드 코일 및/또는 테더 함유 단백질 복합체 및 그의 용도
EP2325311A1 (en) * 2009-11-18 2011-05-25 Pierre Fabre Medicament Novel phage display vector
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
DK2593594T3 (en) 2010-07-16 2017-12-11 Adimab Llc ANTIBODY LIBRARIES
WO2012025530A1 (en) 2010-08-24 2012-03-01 F. Hoffmann-La Roche Ag Bispecific antibodies comprising a disulfide stabilized - fv fragment
US20130245233A1 (en) 2010-11-24 2013-09-19 Ming Lei Multispecific Molecules
JP5766296B2 (ja) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
EP4024029A3 (en) 2011-01-21 2022-09-14 Labrador Diagnostics LLC Systems and methods for sample use maximization
AU2012222833B2 (en) * 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
JP5933001B2 (ja) * 2011-08-10 2016-06-08 コリア・アドヴァンスド・インスティテュート・オブ・サイエンス・アンド・テクノロジー リパーゼ活性が増大した両親媒性ペプチド−リパーゼ結合体及びその用途
US9268915B2 (en) 2011-09-25 2016-02-23 Theranos, Inc. Systems and methods for diagnosis or treatment
US9619627B2 (en) 2011-09-25 2017-04-11 Theranos, Inc. Systems and methods for collecting and transmitting assay results
US8435738B2 (en) 2011-09-25 2013-05-07 Theranos, Inc. Systems and methods for multi-analysis
US8840838B2 (en) 2011-09-25 2014-09-23 Theranos, Inc. Centrifuge configurations
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US9250229B2 (en) 2011-09-25 2016-02-02 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
US10344050B2 (en) * 2011-10-27 2019-07-09 Genmab A/S Production of heterodimeric proteins
CN104011207B (zh) 2011-10-31 2018-09-18 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
KR102274211B1 (ko) * 2011-11-23 2021-07-09 인3바이오 리미티드 재조합 단백질 및 그들의 치료적 용도
WO2013119966A2 (en) 2012-02-10 2013-08-15 Genentech, Inc. Single-chain antibodies and other heteromultimers
US9090694B2 (en) 2012-04-30 2015-07-28 Janssen Biotech, Inc. ST2L antibody antagonists
WO2014001325A1 (en) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
MX354862B (es) 2012-06-27 2018-03-23 Hoffmann La Roche Método para la producción de entidades dirigidas altamente selectivas hechas a la medida y biespecíficas que contienen dos entidades de unión diferentes.
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
KR101963231B1 (ko) * 2012-09-11 2019-03-28 삼성전자주식회사 이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
US10329350B2 (en) * 2012-12-26 2019-06-25 Industrial Technology Research Institute Method for producing a multivalent fab fragment with collagen-like peptide
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
JP6676521B2 (ja) 2013-03-14 2020-04-08 マクロジェニクス，インコーポレーテッド 二重特異性分子、薬学的組成物及びそれらの使用
CN105229465A (zh) 2013-03-15 2016-01-06 赛拉诺斯股份有限公司 用于样品制备的装置、系统和方法
US9902770B2 (en) 2013-03-15 2018-02-27 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
SMT201800503T1 (it) 2013-03-18 2018-11-09 Janssen Pharmaceuticals Inc Anticorpi anti-cd (ox40) umanizzati e loro usi
WO2015035260A1 (en) 2013-09-06 2015-03-12 Theranos, Inc. Systems and methods for detecting infectious diseases
US10370776B2 (en) * 2013-09-25 2019-08-06 Idea Orchard, Llc Antibody like protein
JP6534615B2 (ja) 2013-09-27 2019-06-26 中外製薬株式会社 ポリペプチド異種多量体の製造方法
ES2884255T3 (es) 2013-11-06 2021-12-10 Janssen Biotech Inc Anticuerpos anti-CCL17
SG10201900002QA (en) 2014-01-24 2019-02-27 Dana Farber Cancer Institue Inc Antibody molecules to pd-1 and uses thereof
EP3099717B1 (en) 2014-01-31 2019-03-27 Novartis AG Antibody molecules to tim-3 and uses thereof
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US20150259420A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
GB201409558D0 (en) 2014-05-29 2014-07-16 Ucb Biopharma Sprl Method
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
TWI713453B (zh) 2014-06-23 2020-12-21 美商健生生物科技公司 干擾素α及ω抗體拮抗劑
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
BR112016030740A2 (pt) 2014-07-01 2018-02-20 Pfizer Inc. diacorpos heterodiméricos biespecíficos e seus usos
GB201412659D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
GB201412658D0 (en) 2014-07-16 2014-08-27 Ucb Biopharma Sprl Molecules
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
MX386886B (es) 2014-09-09 2025-03-12 Janssen Biotech Inc Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
EA201790719A1 (ru) 2014-09-26 2017-07-31 Макродженикс, Инк. Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EP3201227A4 (en) 2014-09-29 2018-04-18 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
TWI716362B (zh) 2014-10-14 2021-01-21 瑞士商諾華公司 針對ｐｄ－ｌ１之抗體分子及其用途
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
CN107001482B (zh) 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
AU2015358615B2 (en) 2014-12-04 2021-08-05 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute myeloid leukemia
SG11201706024YA (en) 2015-01-26 2017-08-30 Macrogenics Inc Multivalent molecules comprising dr5-binding domains
JP7082484B2 (ja) 2015-04-01 2022-06-08 中外製薬株式会社 ポリペプチド異種多量体の製造方法
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
MX389805B (es) 2015-05-20 2025-03-11 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
AU2016282674B2 (en) 2015-06-22 2022-01-13 Janssen Biotech, Inc. Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
HRP20240338T1 (hr) 2015-06-24 2024-05-24 Janssen Biotech, Inc. Imunomodulacija i liječenje solidnih tumora s protutijelima koja se specifično vežu na cd38
GB201601073D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies
GB201601077D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibody molecule
GB201601075D0 (en) 2016-01-20 2016-03-02 Ucb Biopharma Sprl Antibodies molecules
EP3878465A1 (en) 2015-07-29 2021-09-15 Novartis AG Combination therapies comprising antibody molecules to tim-3
US20180222982A1 (en) 2015-07-29 2018-08-09 Novartis Ag Combination therapies comprising antibody molecules to pd-1
DK3317301T3 (da) 2015-07-29 2021-06-28 Immutep Sas Kombinationsterapier omfattende antistofmolekyler mod lag-3
WO2017019846A1 (en) 2015-07-30 2017-02-02 Macrogenics, Inc. Pd-1-binding molecules and methods use thereof
PE20180802A1 (es) 2015-08-05 2018-05-09 Janssen Biotech Inc Anticuerpos anti-cd154 y metodos de uso de estos
DK3827845T3 (da) 2015-11-03 2022-05-23 Janssen Biotech Inc Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
GB201521391D0 (en) * 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521382D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Antibodies
GB201521383D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl And Ucb Celltech Method
GB201521389D0 (en) 2015-12-03 2016-01-20 Ucb Biopharma Sprl Method
US10954301B2 (en) 2015-12-14 2021-03-23 Macrogenics, Inc. Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
WO2017106656A1 (en) 2015-12-17 2017-06-22 Novartis Ag Antibody molecules to pd-1 and uses thereof
US20180355043A1 (en) 2015-12-17 2018-12-13 Janssen Biotech, Inc. Antibodies Specifically Binding HLA-DR and Their Uses
HK1254635A1 (zh) 2015-12-17 2019-07-26 Novartis Ag C-met抑制剂与pd-1抗体分子的组合及其用途
EP3393504B1 (en) 2015-12-22 2025-09-24 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
CN108368166B (zh) 2015-12-28 2023-03-28 中外制药株式会社 提高含fc区多肽纯化效率的方法
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
TW201730212A (zh) 2016-02-17 2017-09-01 宏觀基因股份有限公司 Ｒｏｒ１－結合分子及其使用方法
AU2017225733A1 (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (CAR) molecules and uses therefore
US11072666B2 (en) 2016-03-14 2021-07-27 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
US11549099B2 (en) 2016-03-23 2023-01-10 Novartis Ag Cell secreted minibodies and uses thereof
MY209117A (en) 2016-04-15 2025-06-23 Novartis Ag Compositions and methods for selective protein expression
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
US20210177896A1 (en) 2016-06-02 2021-06-17 Novartis Ag Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
JP2019527678A (ja) 2016-06-28 2019-10-03 ユーエムセー・ユトレヒト・ホールディング・ベー・フェー ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
US20190336504A1 (en) 2016-07-15 2019-11-07 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
BR112019001570A2 (pt) 2016-07-28 2019-07-09 Novartis Ag terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1
US20190161542A1 (en) 2016-08-01 2019-05-30 Novartis Ag Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3574009A4 (en) 2017-01-26 2020-11-25 Zlip Holding Limited CD47 ANTIGEN BINDING UNIT AND ITS USES
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
EP3589647A1 (en) 2017-02-28 2020-01-08 Novartis AG Shp inhibitor compositions and uses for chimeric antigen receptor therapy
CN110461358A (zh) 2017-03-31 2019-11-15 公立大学法人奈良县立医科大学 可用于预防和/或治疗凝血因子ⅸ异常、包含代替凝血因子ⅷ的功能的多特异性抗原结合分子的药物组合物
EP3615068A1 (en) 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
UY37758A (es) 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
CN118307674A (zh) 2017-06-22 2024-07-09 诺华股份有限公司 针对cd73的抗体分子及其用途
AU2018292618A1 (en) 2017-06-27 2019-12-19 Novartis Ag Dosage regimens for anti-TIM-3 antibodies and uses thereof
SG11201913137VA (en) 2017-07-11 2020-01-30 Compass Therapeutics Llc Agonist antibodies that bind human cd137 and uses thereof
CN111163798A (zh) 2017-07-20 2020-05-15 诺华股份有限公司 用于抗lag-3抗体的给药方案及其用途
WO2019089753A2 (en) 2017-10-31 2019-05-09 Compass Therapeutics Llc Cd137 antibodies and pd-1 antagonists and uses thereof
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
TW201922291A (zh) 2017-11-16 2019-06-16 瑞士商諾華公司 組合療法
US11851497B2 (en) 2017-11-20 2023-12-26 Compass Therapeutics Llc CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
SG11202005557TA (en) 2017-12-12 2020-07-29 Macrogenics Inc Bispecific cd 16-binding molecules and their use in the treatment of disease
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
SG11202007572VA (en) 2018-02-15 2020-09-29 Macrogenics Inc Variant cd3-binding domains and their use in combination therapies for the treatment of disease
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
MA52571A (fr) 2018-05-08 2021-03-17 Amgen Inc Anticorps bispécifiques ayant des étiquettes appairées à des charges c-terminales clivables
US12012461B2 (en) 2018-05-16 2024-06-18 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
CA3099308A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by nk cells
WO2019226658A1 (en) 2018-05-21 2019-11-28 Compass Therapeutics Llc Multispecific antigen-binding compositions and methods of use
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
UY38251A (es) 2018-06-01 2019-12-31 Novartis Ag Moléculas de unión contra bcma y usos de las mismas
CA3100724A1 (en) 2018-06-13 2019-12-19 Novartis Ag B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof
CN112654394B (zh) 2018-06-19 2025-07-11 阿塔盖有限责任公司 针对补体成分5的抗体分子和其用途
EP3818083A2 (en) 2018-07-03 2021-05-12 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
WO2020021465A1 (en) 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) S.R.L. Method of treatment of neuroendocrine tumors
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof
KR20210106437A (ko) 2018-12-20 2021-08-30 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법 및 약학적 조합물
MX2021007391A (es) 2018-12-20 2021-09-23 Novartis Ag Regimenes de baja dosis extendida para inhibidores de mdm2.
IL284317B2 (en) 2018-12-24 2025-10-01 Sanofi Sa Multispecific binding pseudo-fab proteins
KR20210108421A (ko) 2018-12-24 2021-09-02 사노피 돌연변이 Fab 도메인을 포함하는 다중특이성 결합 단백질
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
CN113490528B (zh) 2019-02-15 2024-12-03 诺华股份有限公司 3-(1-氧代-5-(哌啶-4-基)异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
EP3924055B1 (en) 2019-02-15 2024-04-03 Novartis AG Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
JP7710373B2 (ja) 2019-02-21 2025-07-18 マレンゴ・セラピューティクス，インコーポレーテッド Ｔ細胞関連のがん細胞に結合する多機能性分子およびその使用
AU2020224681A1 (en) 2019-02-21 2021-09-16 Marengo Therapeutics, Inc. Antibody molecules that bind to NKp30 and uses thereof
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
KR20220029546A (ko) 2019-03-29 2022-03-08 아타르가, 엘엘씨 항 fgf23 항체
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
EP3972993A1 (en) 2019-05-21 2022-03-30 Novartis AG Variant cd58 domains and uses thereof
PE20220568A1 (es) 2019-05-21 2022-04-20 Novartis Ag Moleculas de union a cd19 y usos de las mismas
KR20220040483A (ko) 2019-07-26 2022-03-30 얀센 바이오테크 인코포레이티드 칼리크레인 관련 펩티다제 2 항원 결합 도메인을 포함하는 단백질 및 이의 용도
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
AU2020327000A1 (en) 2019-08-08 2022-03-31 Regeneron Pharmaceuticals, Inc. Novel antigen binding molecule formats
TW202120537A (zh) 2019-08-15 2021-06-01 美商健生生物科技公司 用於經改善的單鏈可變片段之材料及方法
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CN114786679A (zh) 2019-10-21 2022-07-22 诺华股份有限公司 具有维奈托克和tim-3抑制剂的组合疗法
CN114786730A (zh) 2019-11-05 2022-07-22 再生元制药公司 N-端scFv多特异性结合分子
PH12022551291A1 (en) 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
MX2022007759A (es) 2019-12-20 2022-07-19 Novartis Ag Combinacion del anticuerpo anti tim-3 mbg453 y anticuerpo anti tgf-beta nis793, con o sin decitabina o el anticuerpo anti pd-1 spartalizumab, para el tratamiento de mielofibrosis y sindrome mielodisplasico.
BR112022012112A2 (pt) 2019-12-20 2022-09-06 Regeneron Pharma Agonistas de il2 e métodos de uso dos mesmos
CN116234829A (zh) 2020-01-03 2023-06-06 马伦戈治疗公司 抗tcr抗体分子及其用途
CN115298322A (zh) 2020-01-17 2022-11-04 贝克顿迪金森公司 用于单细胞分泌组学的方法和组合物
JP2023510393A (ja) 2020-01-17 2023-03-13 ノバルティス アーゲー 骨髄異形成症候群または慢性骨髄単球性白血病の処置に使用するためのｔｉｍ－３阻害剤と低メチル化剤とを含む組合せ
US20230348624A1 (en) 2020-01-30 2023-11-02 Umoja Biopharma, Inc. Bispecific transduction enhancer
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
EP4106813A4 (en) 2020-02-21 2024-03-27 MacroGenics, Inc. CD137 BINDING MOLECULES AND THEIR USES
KR20220147109A (ko) 2020-02-27 2022-11-02 노파르티스 아게 키메라 항원 수용체 발현 세포의 제조 방법
KR20220154728A (ko) 2020-03-13 2022-11-22 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
CN116249549A (zh) 2020-03-27 2023-06-09 诺华股份有限公司 用于治疗增殖性疾病和自身免疫病症的双特异性组合疗法
CN116096758A (zh) 2020-05-01 2023-05-09 诺华股份有限公司 工程化免疫球蛋白
MX2022014239A (es) 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
CN116249714A (zh) 2020-05-27 2023-06-09 詹森生物科技公司 包含cd3抗原结合结构域的蛋白质及其用途
CN115916199A (zh) 2020-06-23 2023-04-04 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案
EP4175650A1 (en) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
PH12023550015A1 (en) 2020-07-16 2024-03-11 Novartis Ag Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
JP2023536818A (ja) 2020-07-29 2023-08-30 ヤンセン バイオテツク，インコーポレーテツド Ｈｌａ－ｇ抗原結合ドメインを含むタンパク質及びそれらの使用
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230321285A1 (en) 2020-08-31 2023-10-12 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
US20230338587A1 (en) 2020-08-31 2023-10-26 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
TW202233672A (zh) 2020-10-22 2022-09-01 美商健生生物科技公司 包括類δ配體３（ＤＬＬ３）抗原結合區之蛋白質及其用途
JP2023547499A (ja) 2020-11-06 2023-11-10 ノバルティス アーゲー 抗体Ｆｃ変異体
US20240025993A1 (en) 2020-11-06 2024-01-25 Novartis Ag Cd19 binding molecules and uses thereof
US20250215081A1 (en) 2020-11-06 2025-07-03 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
KR20230107617A (ko) 2020-11-13 2023-07-17 노파르티스 아게 키메라 항원 수용체(car)-발현 세포를 사용한 병용 요법
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
WO2022162569A1 (en) 2021-01-29 2022-08-04 Novartis Ag Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
CA3210100A1 (en) * 2021-03-01 2022-09-09 Tomoji Mashimo Methods for producing cas3 proteins
BR112023019464A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Anticorpo que tem como alvo cd22 e cd79b
BR112023019458A2 (pt) 2021-03-24 2023-12-05 Janssen Biotech Inc Proteínas que compreendem domínios de ligação ao antígeno de cd3 e usos dos mesmos
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
IL308183A (en) 2021-05-04 2024-01-01 Regeneron Pharma Multispecific FGF21 receptor agonists and their uses
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2022269451A1 (en) 2021-06-22 2022-12-29 Novartis Ag Bispecific antibodies for use in treatment of hidradenitis suppurativa
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202322846A (zh) 2021-08-16 2023-06-16 美商再生元醫藥公司 新穎的il27受體促效劑及其使用方法
WO2023037333A1 (en) 2021-09-13 2023-03-16 Janssen Biotech, Inc CD33 X Vδ2 MULTISPECIFIC ANTIBODIES FOR THE TREATMENT OF CANCER
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
US20250019455A1 (en) 2021-09-24 2025-01-16 Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
EP4423123A1 (en) 2021-10-28 2024-09-04 Novartis AG Engineered fc variants
IL312503A (en) 2021-11-03 2024-07-01 Janssen Biotech Inc Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CA3239224A1 (en) 2021-11-22 2023-05-25 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2023150778A1 (en) 2022-02-07 2023-08-10 Visterra, Inc. Anti-idiotype antibody molecules and uses thereof
US20230357381A1 (en) 2022-04-26 2023-11-09 Novartis Ag Multispecific antibodies targeting il-13 and il-18
EP4522649A1 (en) 2022-05-11 2025-03-19 Regeneron Pharmaceuticals, Inc. Multispecific binding molecule proproteins and uses thereof
WO2023220695A2 (en) 2022-05-13 2023-11-16 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
AU2023276766A1 (en) 2022-05-27 2024-12-05 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
WO2023235848A1 (en) 2022-06-04 2023-12-07 Regeneron Pharmaceuticals, Inc. Interleukin-2 proproteins and uses thereof
TW202435912A (zh) 2022-08-03 2024-09-16 美商航海家醫療公司 用於穿過血腦屏障之組合物及方法
US20240067691A1 (en) 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024040247A1 (en) 2022-08-18 2024-02-22 Regeneron Pharmaceuticals, Inc. Interferon proproteins and uses thereof
IL320562A (en) 2022-11-02 2025-07-01 Janssen Biotech Inc Cancer treatment methods
CN120344558A (zh) * 2022-12-08 2025-07-18 上海星赛生物科技有限公司 双特异性/多特异性抗体及其用途
CN120712281A (zh) 2022-12-16 2025-09-26 瑞泽恩制药公司 结合到aav颗粒的抗原结合分子和用途
US20240252601A1 (en) 2022-12-23 2024-08-01 Regeneron Pharmaceuticals, Inc. Ace2 fusion proteins and uses thereof
EP4649088A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
EP4649092A1 (en) 2023-01-13 2025-11-19 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
IL322890A (en) 2023-02-28 2025-10-01 Regeneron Pharma Multispecific molecules containing an MHC-peptide complex containing an MHC domain and an antigenic peptide and a partially targeted immune cell antigen
KR20250156759A (ko) 2023-02-28 2025-11-03 리제너론 파아마슈티컬스, 인크. 다가 항스파이크 단백질 결합 분자 및 이의 용도
EP4709756A1 (en) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1 binding molecules and methods of use thereof
AU2024274130A1 (en) 2023-05-12 2026-01-08 Regeneron Pharmaceuticals, Inc. Interferon receptor antagonists and uses thereof
KR20260040523A (ko) 2023-06-11 2026-03-24 리제너론 파아마슈티컬스, 인크. 환형화 항체 분자
WO2025034715A1 (en) 2023-08-07 2025-02-13 Janssen Biotech, Inc. Gucy2c antibodies and uses thereof
EP4630457A1 (en) 2023-08-18 2025-10-15 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules and uses thereof
WO2025068957A1 (en) 2023-09-29 2025-04-03 Novartis Ag Bispecific antibodies for use in lowering the risk of cardiovascular disease events in subjects known to be a carrier of clonal expansion of hematopoietic cell lines with somatic mutations
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
US20250179137A1 (en) 2023-12-05 2025-06-05 Regeneron Pharmaceuticals, Inc. Il18 receptor agonists and methods of use thereof
WO2025133340A1 (en) * 2023-12-21 2025-06-26 Ludwig Institute For Cancer Research Ltd Heterodimeric proteins comprising dimerization motifs and methods of using
WO2025199243A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Trivalent multispecific binding molecules and methods of use thereof
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025245494A1 (en) 2024-05-24 2025-11-27 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il12 receptor agonists
US20250376524A1 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Tetravalent multispecific binding molecules and methods of use thereof
WO2025255452A2 (en) 2024-06-07 2025-12-11 Regeneron Pharmaceuticals, Inc. Antigen-binding molecules that bind to aav particles and uses thereof
US20260055171A1 (en) 2024-06-11 2026-02-26 Regeneron Pharmaceuticals, Inc. Vegf antagonists and methods of use thereof
WO2026025058A1 (en) 2024-07-25 2026-01-29 Regeneron Pharmaceuticals, Inc. Aav viral particles retargeted to egfr-expressing cancer cells
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026039791A1 (en) 2024-08-16 2026-02-19 Regeneron Pharmaceuticals, Inc. Tumor-targeted split il2 receptor agonists
WO2026058155A1 (en) 2024-09-11 2026-03-19 Novartis Ag Antibodies targeting il-31
WO2026075989A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Engineered igg molecules and methods of use thereof
WO2026076013A1 (en) 2024-10-01 2026-04-09 Regeneron Pharmaceuticals, Inc. Tumor-targeted il2 receptor agonists and multispecific t-cell engagers

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
DE3852304T3 (de) 1987-03-02 1999-07-01 Enzon Labs Inc., Piscataway, N.J. Organismus als Träger für "Single Chain Antibody Domain (SCAD)".
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9206318D0 (en) 1992-03-24 1992-05-06 Cambridge Antibody Tech Binding substances
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5955341A (en) 1991-04-10 1999-09-21 The Scripps Research Institute Heterodimeric receptor libraries using phagemids
US5858657A (en) 1992-05-15 1999-01-12 Medical Research Council Methods for producing members of specific binding pairs
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
WO1993010247A1 (en) 1991-11-20 1993-05-27 Ab Astra PHASMID VECTOR IN $i(E.COLI)
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
HU215180B (hu) 1992-01-23 1998-10-28 Merck Patent Gmbh. Eljárás monomer és dimer antitest-fragment fúziós fehérjék előállítására
US5233409A (en) 1992-02-25 1993-08-03 Schwab Karl W Color analysis of organic constituents in sedimentary rocks for thermal maturity
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5869337A (en) 1993-02-12 1999-02-09 President And Fellows Of Harvard College Regulated transcription of targeted genes and other biological events
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US6165793A (en) 1996-03-25 2000-12-26 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
US5738996A (en) 1994-06-15 1998-04-14 Pence, Inc. Combinational library composition and method
US5695941A (en) 1994-06-22 1997-12-09 The General Hospital Corporation Interaction trap systems for analysis of protein networks
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
GB9500851D0 (en) 1995-01-17 1995-03-08 Bionvent International Ab Method of selecting specific bacteriophages
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US6130037A (en) 1996-04-25 2000-10-10 Pence And Mcgill University Biosensor device and method
US6083693A (en) 1996-06-14 2000-07-04 Curagen Corporation Identification and comparison of protein-protein interactions that occur in populations
DE69731960T2 (de) 1996-09-24 2005-12-15 Cadus Pharmaceutical Corp. Verfahren und zusammensetzungen für die identifizierung von receptor effectoren
WO1999014319A1 (en) 1997-09-16 1999-03-25 Fox Chase Cancer Center An improved yeast interaction trap assay
AU748358B2 (en) 1997-11-10 2002-06-06 General Hospital Corporation, The Detection systems for registering protein interactions and functional relationships
NZ506071A (en) 1998-02-19 2003-05-30 Harvard College Monovalent, multivalent, and multimeric major histocompatibility complex (MHC) binding domain fusion proteins and conjugates, and uses therefore
AU5639799A (en) 1998-09-07 2000-03-27 Glaxo Group Limited Gaba beta receptor subtypes gaba beta -R1c and GABA beta-R2 and heterodimers thereof
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102459346A (zh) * 2009-04-27 2012-05-16 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9914771B2 (en) 2009-04-27 2018-03-13 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US9309311B2 (en) 2009-04-27 2016-04-12 Oncomed Pharmaceuticals, Inc. Method for making Heteromultimeric molecules
CN102459346B (zh) * 2009-04-27 2016-10-26 昂考梅德药品有限公司 制造异源多聚体分子的方法
US9879084B2 (en) 2011-09-23 2018-01-30 Oncomed Pharmaceuticals, Inc. Modified immunoglobulin molecules that specifically bind human VEGF and DLL4
US10730940B2 (en) 2011-09-23 2020-08-04 Oncomed Pharmaceuticals, Inc. VEGF/DLL4 binding agents and uses thereof
US11512128B2 (en) 2011-09-23 2022-11-29 Mereo Biopharma 5, Inc. VEGF/DLL4 binding agents and uses thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
CN108473556A (zh) * 2015-12-03 2018-08-31 Ucb生物制药私人有限公司 多特异性抗体
CN106905435A (zh) * 2017-03-13 2017-06-30 武汉海沙百得生物技术有限公司 一种制备基于蛋白a突变体的结合蛋白的方法
CN106905435B (zh) * 2017-03-13 2020-04-10 武汉海沙百得生物技术有限公司 一种制备基于蛋白a突变体的结合蛋白的方法
WO2018205755A1 (zh) * 2017-05-09 2018-11-15 安升（上海）医药科技有限公司 多特异性蛋白药物及其文库、以及制备方法和应用
US11331365B2 (en) 2017-05-09 2022-05-17 Assembly Medicine, Llc Multispecific protein drug and library thereof, preparing method therefor and application thereof

Also Published As

Publication number Publication date
EP1421117A4 (en) 2005-12-28
WO2003012069A2 (en) 2003-02-13
US6833441B2 (en) 2004-12-21
WO2003012069A3 (en) 2003-11-06
US20050009139A1 (en) 2005-01-13
EP1421117A2 (en) 2004-05-26
CA2455237A1 (en) 2003-02-13
EP1421117B1 (en) 2013-01-09
CA2455237C (en) 2013-04-09
US7429652B2 (en) 2008-09-30
US20030027247A1 (en) 2003-02-06
CN101654483A (zh) 2010-02-24
JP2005506064A (ja) 2005-03-03
JP2010053132A (ja) 2010-03-11
MXPA04001053A (es) 2005-02-17

Similar Documents

Publication Publication Date Title
CN1558916A (zh) 产生嵌合异源多聚体的组合物和方法
US12180299B2 (en) Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
US20210047387A1 (en) Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species
CN1956996A (zh) 基于泛素蛋白的人工结合蛋白的生产
CN1662556A (zh) 在胞内环境中表现出增强的稳定性的免疫球蛋白构架及其鉴定方法
CN1173878A (zh) 双功能或双价抗体片段类似物
JP5508002B2 (ja) 免疫グロブリンのエンジニアリング方法
CN1871256A (zh) 泪脂质运载蛋白的突变蛋白
CN1856571A (zh) 连接目标序列的方法
CN1946422A (zh) 针对血管内皮生长因子的人源化抗体
CN1678634A (zh) 免疫球蛋白单个变体抗原结合区及其特异性构建体
JP5955773B2 (ja) 改善された細菌膜タンパク質分泌
CN1829806A (zh) 产生高亲和力抗体的方法
CN1688338A (zh) 对免疫系统分子进行人源化的方法
CN1607959A (zh) 导致或引起包括淋巴瘤细胞在内的细胞杀伤的人多肽
CN1606569A (zh) 具有mn结合和细胞粘附中和活性的人类抗体
CN1946741A (zh) 金结合蛋白及其用途
CN1551886A (zh) 用于选择性癌症治疗的特异性人抗体
US20240034809A1 (en) Heterodimeric iga fc constructs and methods of use thereof
CN1756761A (zh) 识别靶的结合剂
CN1444651A (zh) 在酵母中生产抗体文库以及抗体文库的应用
CN1823164A (zh) 从多肽全能文库恢复可逆可解折叠多肽的方法
CN1073158C (zh) 抗表皮生长因子受体的单链可变区片段和抗体
CA3167854C (en) Heterodimeric iga fc constructs and methods of use thereof
CA2982131C (en) Methods for purifying heterodimeric multispecific antibodies from parental homodimeric antibody species

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication